Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review TORONTO, ON – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced its New Drug Submission (NDS) for exagamglogene autotemcel (exa-cel)… Read More
VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced the… Read More
VANCOUVER, BC – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) is pleased to announce the closing of its previously announced public offering (the “Offering”) including the full exercise of the underwriters’… Read More
In a time where medical assistance is critical, Getinge donates extensive medical equipment to Ukraine. The donation, made in collaboration with the Ministry of Health Ukraine, includes a significant number… Read More
